Byonyks has FDA clearance for a home dialysis cycler. Medicare's price per night is the next test

On 28 October the US Centers for Medicare and Medicaid Services set the 2027 base payment for a dialysis treatment at $297.52, up $15.81 from $281.71. Of that rise, $12.85 comes from folding phosphate binders into the bundle, so the underlying increase is $2.96, or about 1 percent. That is the figure on which Byonyks, a company that filed from Lahore, would have to build a US business. Its X1 home dialysis cycler was cleared by the US Food and Drug Administration on 16 May 2025, and clearance was the cheaper half of the job.

What the FDA record says

The 510(k) is numbered K243371. The FDA received it on 30 October 2024 and decided on 16 May 2025, 198 calendar days later, a span that includes any time the agency waited for answers from the company. It is a Traditional submission, was not reviewed by a third party, and falls under regulation 876.5630. The product code is FKX for the cycler and KDJ for the disposable administration set, which the filing calls the DS1. The applicant is Byonyks Pvt Ltd of Lahore, while the company's own releases give Chicago as its headquarters, and it announced the clearance only on 3 February 2026.

The decision is "substantially equivalent". That means the agency found the cycler as safe and effective as a device already on the market, not that it is better, so any claim of superiority belongs to the company. The usability testing behind the filing was run by the consultancy Design Science, which says it recreated a simulated clinical lab at Byonyks' own facility and tested patients and caregivers as users.

From Robo Kidney to a cycler

Byonyks first appeared in Pakistani coverage in August 2020, when ProPakistani reported a Lahore startup with a home dialysis machine called Robo Kidney, which its founder, Farrukh Usman, described as affordable and bloodless. The article said the machine would go into mass production in the coming few months after approval from health regulators. The company said in 2022 that it had laid the foundation of a factory in Lahore in 2021, won a certificate from the Drug Regulatory Authority of Pakistan in October 2022 and employed about 80 engineers. Those are company statements, made in sponsored content.

The FDA clearance came four years and nine months after that first article, and the 198 day review is a small part of the gap. The rest was development, testing and the documentation a US filing demands. A reader judging the company should count that interval, not the review, as the cost of getting from announcement to a market that pays.

What reached the FDA is a peritoneal dialysis cycler. In this therapy a machine pumps dialysis fluid into the patient's abdomen and drains it after a set time, using the lining of the abdomen as the filter, so no blood leaves the body. Automated versions run overnight at home. Usman has said that every peritoneal dialysis device on the market is 10 to 30 years old, and the company's case is a newer machine with easier controls. Byonyks says overseas licences have supported more than 10,000 therapies and does not define the unit.

The arithmetic of a night

Medicare pays dialysis facilities a single bundled rate per treatment, the same for every modality. The policy allows three payments a week, and for a 30 day month payment is limited to 13 treatments. At the 2026 base rate of $281.71, three payments a week is $845.13, or $43,947 over 52 weeks, before the adjustments for each patient's age, size and health and before a home training add on.

Now divide by what the machine does. A patient on an automated cycler normally uses it every night, so the facility is paid for three treatments a week and supplies seven nights of fluid and tubing. That is 2.33 disposable sets for every payment (7 divided by 3). Spread over a year, the base rate comes to $43,947 divided by 365, or $120.40 a night. From that a provider has to cover the dialysis fluid, the tubing set, the cycler itself, nursing time for training and monitoring, laboratory work and administration. The set is where a cycler maker earns, in the way a printer maker earns on cartridges, and every dollar added to its price comes off the provider's margin. At $10, a set would absorb 8.3 percent of the night's payment. Byonyks has not published a price for the cycler or the set.

A home patient does not occupy a chair, a nurse's station or a slot on a clinic's shift. That is the provider's gain, and it is why home therapy can pay even when the rate is the same. The cost comes earlier, in training, and the new rules lean on it. CMS raised the add on for training patients in home and self dialysis from $95.60 to $138.00, an increase of $42.40 or 44 percent. Training is the usual bottleneck for home dialysis, so the rise helps every home dialysis supplier, not only Byonyks.

The 2027 base rate also needs care. On the same three a week basis, $297.52 is $46,413 a year and $127.16 a night, which is $6.76 a night more than in 2026. Of that, $5.49 a night is the $12.85 added for binders, a cost the provider now carries. The real gain is $2.96 a payment, about $1.27 a night, or 1 percent. A cycler maker that raised its set price by even a few dollars would take more than that away.

Who has to say yes

Medicare pays facilities, not manufacturers. A US buyer is a dialysis provider, and it would have to stock an unfamiliar cycler, train nurses and patients on it, and trust a new supply chain for the disposable set. Clearance gives Byonyks the right to sell. It does not give it a customer, and a provider that signs on is committing to a recurring purchase of disposable sets from a supplier whose US record so far is a single clearance. The company says 85 percent of Americans on dialysis do not receive peritoneal dialysis, so the opening is real, but it is an opening that the established makers of peritoneal dialysis equipment also serve, with long relationships and installed machines.

The company's February release says it is planning to enter the US market and building operational infrastructure there, and names no provider partner, price or launch date. It also describes advanced development programmes for further peritoneal dialysis products, which would have to clear the same sums.

Who gains, and what decides it

Patients who can manage treatment at home gain a choice, and providers gain a way to treat them without a chair three times a week. Pakistan gains a regulated medical device exporter with engineers in Lahore. The outcome rests on three numbers that Byonyks has not published: the price of the set, the price of the cycler and the number of providers who will take it. The company has published no accounts and no verified funding figure.

The 2027 rates apply to services from 1 January 2027, the first date on which a US facility could be paid the $297.52 base rate and the $138.00 training add on for a patient using an X1, if one has been sold by then.